Search
Bristol-Myers Squibb Co
BMYAdd to Watchlist
61.530USD
+0.770+1.27%
Close 07-23 16:00（ET）Quotes delayed by 15 min
123.86BMarket Cap
17.22P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Bristol-Myers Squibb Co is 6.94, ranking 120 out of 155 in the Pharmaceuticals industry. The average price target is 53.00, with a high of 68.00 and a low of 33.10.
Analyst Rating
Based on
31
analysts
Hold
Current Rating
63.100
Target Price
+3.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Bristol-Myers Squibb Co
BMY
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Bristol-Myers Squibb Co's expected revenue for the next quarter?
Bristol-Myers Squibb Co's expected revenue is 11.74B.
What is Bristol-Myers Squibb Co's price target?
Analysts forecast that Bristol-Myers Squibb Co's price target is USD 53.00, with the highest forecast at USD 68.00 and the lowest forecast at USD 33.10.
How have Bristol-Myers Squibb CoBMY's recent earnings per share performed?
The market expectation was USD 1.31, while Bristol-Myers Squibb CoBMY's earnings per share (EPS) for the previous quarter was USD 0.53. EPS for the next quarter is expected at USD 1.59.
What is the analyst rating for Bristol-Myers Squibb Co?
Based on the ratings of Bristol-Myers Squibb Co's stock from 31 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.